WALTHAM, Mass., Nov. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the hepatitis C virus drug market in Russia will grow nine percent annually over the 2008 - 2013 study period, reaching $327 million by 2013. This growth will be driven mainly by increased government spending on healthcare and increased use of more-expensive therapies like pegylated interferons [peg-IFNs] (i.e., Roche's Pegasys and Schering-Plough's PegIntron) instead of conventional interferons (i.e., Roche's Roferon and Schering-Plough's Intron A).
As Russia's gross domestic product (GDP) per capita continues to grow, both government and private healthcare spending is expected to increase as well. In 2007, the International Monetary Fund reported government spending on healthcare was only about 3.5 percent of Russia's GDP, but the World Bank and other sources expect this number to increase to 5.5 percent of Russia's GDP by 2013.
The new Emerging Markets report entitled Hepatitis C Virus in Russia also finds that Pegasys and PegIntron will benefit from market growth in Russia. Sales of these two agents will account for 77 percent of the total hepatitis C virus drug market in 2013, an increase from 68 percent in 2008.
"In Russia, Pegasys and PegIntron currently capture a relatively small patient share but have growth potential because physicians and patients perceive them to be more effective and safer than conventional interferons," stated Alexandra Makarova, M.D., Ph.D., analyst at Decision Resources.
The new report is part of an expansion of the Emerging Markets report series to cover Russia. The series contains primary research of physicians and epidemiology study in key pharmaceutical markets of Russia -- Moscow, Saint Petersburg and Novosibirsk.
About Emerging Markets Reports
Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Gisselle Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
SOURCE Decision Resources
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved